Brokerages Anticipate Cascadian Therapeutics, Inc. (CASC) Will Post Earnings of -$0.29 Per Share

Equities research analysts expect Cascadian Therapeutics, Inc. (NASDAQ:CASC) to announce earnings of ($0.29) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics posted earnings of ($0.47) per share during the same quarter last year, which would indicate a positive year over year growth rate of 38.3%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 8th.

On average, analysts expect that Cascadian Therapeutics will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.14). For the next year, analysts forecast that the business will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.22) to ($0.69). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Cascadian Therapeutics.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. During the same period in the previous year, the business posted ($0.09) earnings per share.

CASC has been the subject of a number of research analyst reports. Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Monday, November 13th. Cowen reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. Cantor Fitzgerald reiterated a “hold” rating and issued a $4.00 price objective on shares of Cascadian Therapeutics in a report on Thursday, August 31st. ValuEngine downgraded Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Barclays began coverage on Cascadian Therapeutics in a report on Wednesday, September 6th. They issued an “underweight” rating and a $4.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Cascadian Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.63.

Large investors have recently modified their holdings of the company. State of Wisconsin Investment Board purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $104,000. New York State Common Retirement Fund purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $136,000. BB&T Securities LLC purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $143,000. Rhumbline Advisers purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $143,000. Finally, Bank of America Corp DE boosted its position in shares of Cascadian Therapeutics by 2,316.5% during the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 35,975 shares during the last quarter. Hedge funds and other institutional investors own 80.35% of the company’s stock.

Shares of Cascadian Therapeutics (NASDAQ CASC) traded down $0.13 during mid-day trading on Thursday, reaching $3.92. The company had a trading volume of 544,900 shares, compared to its average volume of 297,120. Cascadian Therapeutics has a 12 month low of $3.18 and a 12 month high of $6.72.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Cascadian Therapeutics, Inc. (CASC) Will Post Earnings of -$0.29 Per Share” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2017/12/07/brokerages-anticipate-cascadian-therapeutics-inc-casc-will-post-earnings-of-0-29-per-share.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply